Search Results - "Dahlstrom, Ulf"

Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study by Tromp, Jasper, Bamadhaj, Sahiddah, Cleland, John G F, Angermann, Christiane E, Dahlstrom, Ulf, Ouwerkerk, Wouter, Tay, Wan Ting, Dickstein, Kenneth, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V, Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Lam, Carolyn S P, Filippatos, Gerasimos, Collins, Sean P

“…Heart failure is a global public health problem, affecting a large number of individuals from low-income and middle-income countries. REPORT-HF is, to our…”
Get full text

Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure by Savarese, Gianluigi, Vedin, Ola, D'Amario, Domenico, Uijl, Alicia, Dahlström, Ulf, Rosano, Giuseppe, Lam, Carolyn S.P., Lund, Lars H.

“…This study sought to evaluate the incidence, the predictors, and the associations with outcomes of changes in ejection fraction (EF) in heart failure (HF)…”
Get full text

Association between enrolment in a heart failure quality registry and subsequent mortality—a nationwide cohort study by Lund, Lars H., Carrero, Juan‐Jesus, Farahmand, Bahman, Henriksson, Karin M., Jonsson, Åsa, Jernberg, Tomas, Dahlström, Ulf

“…Aims Heart failure (HF) quality registries report quality of care but it is unknown whether they improve outcomes. The aims were to assess predictors of…”
Get full text

Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients by Ahmad, Tariq, Lund, Lars H., Rao, Pooja, Ghosh, Rohit, Warier, Prashant, Vaccaro, Benjamin, Dahlström, Ulf, O'Connor, Christopher M., Felker, G. Michael, Desai, Nihar R.

“…Background Whereas heart failure (HF) is a complex clinical syndrome, conventional approaches to its management have treated it as a singular disease, leading…”
Get full text

Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure by Johansson, Isabelle, MD, PhD Fellow, Dahlström, Ulf, MD, PhD, Edner, Magnus, MD, PhD, Näsman, Per, PhD, Rydén, Lars, MD, PhD, Norhammar, Anna, MD, PhD

“…Abstract Background Heart failure (HF) is a common and serious complication in type 2 diabetes mellitus (T2DM). The prognosis of ischemic HF and impact of…”
Get full text

A comprehensive population‐based characterization of heart failure with mid‐range ejection fraction by Koh, Angela S., Tay, Wan Ting, Teng, Tiew Hwa Katherine, Vedin, Ola, Benson, Lina, Dahlstrom, Ulf, Savarese, Gianluigi, Lam, Carolyn S.P., Lund, Lars H.

“…Aims Clinical features and outcomes in the novel phenotype heart failure with mid‐range ejection fraction [HFmrEF, ejection fraction (EF) 40–49%] were compared…”
Get full text

Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology by Lainscak, Mitja, Blue, Lynda, Clark, Andrew L., Dahlström, Ulf, Dickstein, Kenneth, Ekman, Inger, McDonagh, Theresa, McMurray, John J., Ryder, Mary, Stewart, Simon, Strömberg, Anna, Jaarsma, Tiny

“…Guidelines on heart failure (HF) stress the importance of lifestyle advice, although there is little evidence that such recommendations improve symptoms or…”
Get full text

Eligibility for vericiguat in a real‐world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure Registry by Nguyen, Ngoc V., Lindberg, Felix, Benson, Lina, Ferrannini, Giulia, Imbalzano, Egidio, Mol, Peter G.M., Dahlström, Ulf, Rosano, Giuseppe M.C., Ezekowitz, Justin, Butler, Javed, Lund, Lars H., Savarese, Gianluigi

“…Aim We investigated the eligibility for vericiguat in a real‐world heart failure (HF) population based on trial, guideline and label criteria. Methods and…”
Get full text

Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction by Uijl, Alicia, Savarese, Gianluigi, Vaartjes, Ilonca, Dahlström, Ulf, Brugts, Jasper J., Linssen, Gerard C.M., Empel, Vanessa, Brunner‐La Rocca, Hans‐Peter, Asselbergs, Folkert W., Lund, Lars H., Hoes, Arno W., Koudstaal, Stefan

“…Aims We aimed to derive and validate clinically useful clusters of patients with heart failure with preserved ejection fraction (HFpEF; left ventricular…”
Get full text

Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study by Vedin, Ola, Lam, Carolyn S P, Koh, Angela S, Benson, Lina, Teng, Tiew Hwa Katherine, Tay, Wan Ting, Braun, Oscar Ö, Savarese, Gianluigi, Dahlström, Ulf, Lund, Lars H

“…The pathogenic role of ischemic heart disease (IHD) in heart failure (HF) with reduced ejection fraction (HFrEF; EF <40%) is well established, but its…”
Get full text

State of the art: Using natriuretic peptide levels in clinical practice by Maisel, Alan, Mueller, Christian, Adams Jr, Kirkwood, Anker, Stefan D., Aspromonte, Nadia, Cleland, John G.F., Cohen-Solal, Alain, Dahlstrom, Ulf, DeMaria, Anthony, Di Somma, Salvatore, Filippatos, Gerasimos S., Fonarow, Gregg C., Jourdain, Patrick, Komajda, Michel, Liu, Peter P., McDonagh, Theresa, McDonald, Kenneth, Mebazaa, Alexandre, Nieminen, Markku S., Peacock, W. Frank, Tubaro, Marco, Valle, Roberto, Vanderhyden, Marc, Yancy, Clyde W., Zannad, Faiez, Braunwald, Eugene

“…Natriuretic peptide (NP) levels (B-type natriuretic peptide (BNP) and N-terminal proBNP) are now widely used in clinical practice and cardiovascular research…”
Get full text

Eligibility for omecamtiv mecarbil in a real-world heart failure population: Data from the Swedish Heart Failure Registry by Lindberg, Felix, Øigaard, Natanael, Metra, Marco, Rosano, Giuseppe M C, Dahlström, Ulf, Mol, Peter, Hage, Camilla, Lund, Lars H, Savarese, Gianluigi

“…We assessed eligibility for omecamtiv mecarbil (OM) in a real-world cohort with heart failure with reduced ejection fraction (HFrEF) according to the selection…”
Get full text

Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction by Tromp, Jasper, Ouwerkerk, Wouter, Teng, Tiew-Hwa K, Cleland, John G F, Bamadhaj, Sahiddah, Angermann, Christiane E, Dahlstrom, Ulf, Tay, Wan Ting, Dickstein, Kenneth, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V, Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Collins, Sean P, Filippatos, Gerasimos, Lam, Carolyn S P

“…Abstract Background Heart failure (HF) is a global challenge, with lower- and middle-income countries (LMICs) carrying a large share of the burden. Treatment…”
Get full text

Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry by Becher, Peter Moritz, Schrage, Benedikt, Benson, Lina, Fudim, Marat, Corovic Cabrera, Carin, Dahlström, Ulf, Rosano, Giuseppe M.C., Jankowska, Ewa A., Anker, Stefan D., Lund, Lars H., Savarese, Gianluigi

“…Aims Iron deficiency (ID) is associated with poor prognosis regardless of anaemia. Intravenous iron improves quality of life and outcomes in patients with ID…”
Get full text

Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design by Savarese, Gianluigi, Settergren, Camilla, Schrage, Benedikt, Thorvaldsen, Tonje, Löfman, Ida, Sartipy, Ulrik, Mellbin, Linda, Meyers, Andrea, Farsani, Soulmaz Fazeli, Brueckmann, Martina, Brodovicz, Kimberly G., Vedin, Ola, Asselbergs, Folkert W., Dahlström, Ulf, Cosentino, Francesco, Lund, Lars H.

“…Comorbidities may differently affect treatment response and cause-specific outcomes in heart failure (HF) with preserved (HFpEF) vs. mid-range/mildly-reduced…”
Get full text

Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population by Thorvaldsen, TONJE, FERRANNINI, GIULIA, MELLBIN, LINDA, BENSON, LINA, COSENTINO, FRANCESCO, MCMURRAY, JOHN J.V., DAHLSTRÖM, ULF, LUND, LARS H., SAVARESE, GIANLUIGI

“…•Eligibility for empagliflozin and dapagliflozin ranges from 30% to 35% when strictly applying DAPA-HF, DELIVER, and EMPEROR trials selection criteria to a…”
Get full text

The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: Data from the Swedish Heart Failure Registry by Tomasoni, Daniela, Vitale, Cristiana, Guidetti, Federica, Benson, Lina, Braunschweig, Frieder, Dahlström, Ulf, Melin, Michael, Rosano, Giuseppe M.C., Lund, Lars H., Metra, Marco, Savarese, Gianluigi

“…ABSTRACT Aims The aim of this analysis was to provide data on the overall comorbidity burden, both cardiovascular (CV) and non‐CV, in a large real‐world heart…”
Get full text

EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot) by Maggioni, Aldo P., Dahlström, Ulf, Filippatos, Gerasimos, Chioncel, Ovidiu, Leiro, Marisa Crespo, Drozdz, Jaroslaw, Fruhwald, Friedrich, Gullestad, Lars, Logeart, Damien, Fabbri, Gianna, Urso, Renato, Metra, Marco, Parissis, John, Persson, Hans, Ponikowski, Piotr, Rauchhaus, Mathias, Voors, Adriaan A., Nielsen, Olav Wendelboe, Zannad, Faiez, Tavazzi, Luigi

“…Aims The ESC‐HF Pilot survey was aimed to describe clinical epidemiology and 1‐year outcomes of outpatients and inpatients with heart failure (HF). The pilot…”
Get full text

Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry by Becher, Peter M., Schrage, Benedikt, Ferrannini, Giulia, Benson, Lina, Butler, Javed, Carrero, Juan Jesus, Cosentino, Francesco, Dahlström, Ulf, Mellbin, Linda, Rosano, Giuseppe M.C., Sinagra, Gianfranco, Stolfo, Davide, Lund, Lars H., Savarese, Gianluigi

“…Aims Use of sodium–glucose co‐transporter 2 inhibitors (SGLT2i) in real‐world heart failure (HF) is poorly characterised. In contemporary patients with HF and…”
Get full text

Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence by Janse, Roemer J., Fu, Edouard L., Dahlström, Ulf, Benson, Lina, Lindholm, Bengt, Diepen, Merel, Dekker, Friedo W., Lund, Lars H., Carrero, Juan‐Jesus, Savarese, Gianluigi

“…Aim Half of heart failure (HF) patients have chronic kidney disease (CKD) complicating their pharmacological management. We evaluated physicians' and patients'…”
Get full text